Successful Treatment of Systemic Lupus Erythematosus with Subcutaneous Immunoglobulin

Brasileiro, A; Fonseca Oliveira, J; Pinheiro, S; Paiva-Lopes, MJ

http://hdl.handle.net/10400.17/2847

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
Lupus 2016 663.pdf		276.37 KB	Adobe PDF	Download

Send Feedback

Authors

Abstract(s)

The therapeutic efficacy of high-dose intravenous immunoglobulin in systemic lupus erythematosus (SLE) patients is well established. However, side effects might limit its use and lead to the consideration of therapeutic alternatives, such as the subcutaneous formulation of immunoglobulin, which has been used in some patients with other autoimmune diseases. We report a case of SLE refractory to classical therapies. High-dose intravenous immunoglobulin was effective, but gave rise to significant side effects. The patient was successfully treated with subcutaneous human immunoglobulin, achieving and maintaining clinical and laboratory remission. A lower immunoglobulin dose was needed and no side effects were observed, compared to the intravenous administration. Subcutaneous immunoglobulin could be a better-tolerated and cost-saving therapeutic option for select SLE patients.

Keywords

Dose-Response Relationship, Drug Female Humans Immunoglobulins Immunoglobulins, Intravenous Immunologic Factors Injections, Subcutaneous Lupus Erythematosus, Systemic Middle Aged Treatment Outcome HSAC DER HSAC MED